Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment

Seminars in Oncology

Volumn 36, Issue SUPPL. 2, 2009, Pages

  Chamberlain, Marc C ^a   Glantz, Michael ^b   Groves, Morris D ^c   Wilson, Wyndham H ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CHEMOKINE; CHEMOKINE CCL18; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METHOTREXATE; PREDNISONE; RITUXIMAB; TOPOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE;

ARTICLE; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CYTOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; MULTIPLE CYCLE TREATMENT; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR GROWTH;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FLOW CYTOMETRY; HUMANS; LEUKEMIA; LEUKEMIC INFILTRATION; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MENINGES;

EID: 67849089116     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.05.005     Document Type: Article

References (56)

1. Posner J.B. Leptomeningeal metastases. Neurologic complications of cancer. (ed 1) vol 45 (1995), Oxford University Press, New York 143-171
2. Chamberlain M.C. Neoplastic meningitis. Neurologist 12 (2006) 179-187
3. Glass J.P., Melamed M., Chernik N.L., and Posner J.B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29 (1979) 1369-1375
4. Enting R.H. Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res 125 (2005) 17-30
5. Chamberlain M.C., and Junck L. Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated?. Expert Rev Neurother 4 Suppl (2004) S3-S10
6. Glantz M.J., Chamberlain M.C., and Walters B.C. Diagnosis and outcome measures in trials for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus 4 (1998) 8-16
7. Chamberlain M.C., and Kormanik P.A. Carcinomatous meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55 (1998) 506-512
8. Chamberlain M.C., and Kormanik P. Prognostic significance of co-existent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 54 (1997) 1364-1368
9. Harstad L., Hess K.R., and Groves M.D. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neurooncology 10 (2008) 1010-1018
10. Chamberlain M.C., and Kormanik P. Prognostic significance of 111 indium-DTPA CSF flow studies. Neurology 46 (1996) 1674-1677
11. Chamberlain M.C., and Tsao-Wei D. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology 63 (2005) 2159-2161
12. Chamberlain M.C., Glantz M.J., and Johnston S. Neoplastic meningitis: prognostic significance of Karnofsky performance status. Arch Neurol 66 (2009) 74-78
13. Glantz M.J., Cole B.F., Glantz L.K., Cobb J., Mills P., Lekos A., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82 (1998) 733-739
14. Chamberlain M.C., Kormanik P.A., and Glantz M.J. A comparison between ventricular and lumbar CSF cytology in adult patients with leptomeningeal metastases. Neurooncology 3 (2001) 42-45
15. Chamberlain M.C., Sandy A., and Press G.A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40 (1990) 435-438
16. Zeiser R., Burger J.A., Bley T.A., Windfuhr-Blum M., Schulte-Monting J., and Behringer D.M. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis-a single centre experience. Br J Haematol 124 (2004) 762-768
17. van Besien K., Ha C.S., Murphy S., McLaughlin P., Rodriguez A., Amin K., et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate grade and immunoblastic lymphoma. Blood 91 (1998) 1178-1184
18. Hollender A., Kvaloy S., Nome O., Skovlund E., Lote K., and Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 13 (2002) 1099-1107
19. Hegde U., Filie A., Little R.F., Janik J.E., Grant N., Steinberg S.M., et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105 (2005) 496-502
20. French C.A., Dorfman D.M., Shaheen G., and Cibas E.S. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 23 (2000) 369-374
21. Bromberg J.E.C., Breems D.A., Kraan J., Bikker G., van der Holt B., Sillevis Smitt P., et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 68 (2008) 1674-1679
22. Brem S.S., Bierman P.J., Black P., Brem H., Chamberlain M., Chiocca E.A., et al. NCCN clinical practice guidelines in oncology. Central nervous system cancers. V.1.2008 ed. http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf Accessed January 23, 2009
23. Rhodes C.H., Glantz M.J., Glantz L., Lekos A., Sorenson G.D., Honsinger C., et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 77 (1996) 543-548
24. Gleissner B., Siehl J., Korfel A., Reinhardt R., and Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58 (2002) 390-396
25. Chamberlain M.C. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 50 (1998) 1173-1175
26. Twijnstra A., Ongerboer de Visser B.W., van Zanten A.P., Hart A.A., and Nooyen W.J. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 7 (1989) 57-63
27. Boehme V., Zeynalova S., Kloess M., Loeffler M., Kaiser U., Pfreundschuh M., et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18 (2007) 149-157
28. Yoshida S., and Morii K. Intrathecal chemotherapy for patients with meningeal carcinomatosis. Surg Neurol 63 (2005) 52-55
29. Groves M.D. The pathogenesis of neoplastic meningitis. Curr Oncol Rep 5 (2003) 15-23
30. Brandsma D., Voest E.E., de Jager W., Bonfrer H., Algra A., Boogerd W., et al. CSF protein profiling using Multiplex Immuno-assay: a potential new diagnostic tool for leptomeningeal metastases. J Neurol 253 (2006) 1177-1184
31. van de Langerijt B., Gijtenbeek J.M., de Reus H.P., Sweep F.C., Geurts-Moespot A., Hendriks J.C., et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 67 (2006) 114-119
32. Reijneveld J.C., Brandsma D., Boogerd W., Bonfrer J.G., Kalmijn S., Voest E.E., et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 65 (2005) 1120-1122
33. Friedberg M.H., Glantz M.J., Klempner M.S., Cole B.F., and Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 82 (1998) 923-930
34. Herrlinger U., Wiendl H., Renninger M., Förschler H., Dichgans J., and Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91 (2004) 219-224
35. Stockhammer G., Poewe W., Burgstaller S., Deisenhammer F., Muigg A., Kiechl S., et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54 (2000) 1670-1676
36. Nagai A., Terashima M., Harada T., Shimode K., Takeuchi H., Murakawa Y., et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 329 (2003) 53-60
37. Roy S., Josephson S.A., Fridlyand J., Karch J., Kadoch C., Karrim J., et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 26 (2008) 96-105
38. Chamberlain M.C., and Corey-Bloom J. Leptomeningeal metastasis: Indium-DTPA CSF flow studies. Neurology 41 (1991) 1765-1769
39. Groves M.D. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 66 (2006) 1609-1610
40. Mehta M.P., Shapiro W.R., Glantz M.J., Patchell R.A., Weitzner M.A., Meyers C.A., et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20 (2002) 3445-3453
41. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
42. Meyers C.A., Smith J.A., Bezjak A., Mehta M.P., Liebmann J., Illidge T., et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22 (2004) 157-165
43. Chamberlain M.C., and Johnston S.K. Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer 115 (2009) 1941-1946
44. Chamberlain M.C. Neoplastic meningitis. Oncologist 13 (2008) 967-977
45. Groves M.D., Glantz M.J., Chamberlain M.C., Baumgartner K.E., Conrad C.A., Hsu S., et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neurooncology 10 (2008) 208-215
46. Chamberlain M.C., and Kormanik P. Leptomeningeal metastases due to melanoma: combined modality therapy. Int J Oncol 9 (1996) 505-510
47. Chamberlain M.C., and Kormanik P.A. Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology 49 (1997) 1728-1731
48. Chamberlain M.C., and Kormanik P.A. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35 (1997) 55-64
49. Gabos Z., Sinha R., Hanson J., Chauhan N., Hugh J., Mackey J.R., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24 (2006) 5658-5663
50. Wolstenholme V., Hawkins M., Ashley S., Tait D., and Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 17 (2008) 661-665
51. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment. The M77001 Study Group. J Clin Oncol 23 (2005) 4265-4274
52. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100 (2008) 1092-1103
53. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
54. Melisko M.E., Glantz M., and Rugo H.S. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 6 (2009) 25-33
55. Chamberlain M.C. Risk of neoplastic meningitis following surgical resection of cerebellar metastases. J Neurooncol 89 (2008) 105-107
56. Suki D., Abouassi H., Patel A.J., Sawaya R., Weinberg J.S., and Groves M.D. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 108 (2008) 248-257